Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma

2.1 Pembrolizumab (Keytruda, MSD) is indicated 'for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage 2B, 2C or 3 melanoma and who have undergone complete resection'.

2.2 Pembrolizumab is also recommended for the adjuvant treatment of resected stage 3 melanoma (NICE technology appraisal guidance 766).

2.3 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.4 The list price is £2,630.00 per 100 mg/4 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed August 2022).

2.5 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.